Methylene blue in place of acridine orange as a photosensitizer in photodynamic therapy of osteosarcoma

In Vivo

Volumn 22, Issue 3, 2008, Pages 297-304

  Matsubara, Takao ^a   Kusuzaki, Katsuyuki ^a,b   Matsumine, Akihiko ^a   Satonaka, Haruhiko ^a   Shintani, Ken ^a   Nakamura, Tomoki ^a   Uchida, Atsumasa ^a  

^a Mei Postgraduate School of Medicine   (Japan)

^b Department of Orthopaedic Surgery   (Japan)

Author keywords

Acridine orange; Methylene blue; Osteosarcama; Photodynamic therapy

Indexed keywords

ACRIDINE ORANGE; METHYLENE BLUE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA; PHOTODYNAMIC THERAPY; RADIOSENSITIVITY;

EID: 45949100667     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Rhodes LE, de Rie MA, Leifsdottir R, Yu RC, Bachmann I, Goulden V, Wong GA, Richard MA, Anstey A and Wolf P: Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 143: 1131-1136, 2007.
2. Bendsoe N, Persson L, Johansson A, Axelsson J, Svensson J, Gräfe S, Trebst T, Andersson-Engels S, Svanberg S and Svanberg K: Fluorescence monitoring of a topically applied liposomal Temoporfin formulation and photodynamic therapy of nonpigmented skin malignancies. J Environ Pathol Toxicol Oncol 26: 117-126, 2007.
3. Fien SM and Oseroff AR: Photodynamic therapy for non-melanoma skin cancer. J Natl Compr Canc Netw 5: 531-540, 2007.
4. Tokar JL, Haluszka O and Weinberg DS: Endoscopic therapy of dysplasia and early-stage cancers of the esophagus. Semin Radiat Oncol 17: 10-21, 2007.
5. Eickhoff A, Jakobs R, Weickert U, Hartmann D, Schilling D, Alsenbesy M, Eickhoff JC and Riemann JF: Long-segment early squamous cell carcinoma of the proximal esophagus: curative treatment and long-term follow-up after 5-aminolevulinic acid (5-ALA)-photodynamic therapy. Endoscopy 38: 641-643, 2006.
6. Ross P Jr, Grecula J, Bekaii-Saab T, Villalona-Calero M, Otterson G and Magro C: Incorporation of photodynamic therapy as an induction modality in non-small cell lung cancer. Lasers Surg Med 38: 881-889, 2006.
7. Mortman KD and Frankel KM: Pulmonary resection after successful downstaging with photodynamic therapy. Ann Thorac Surg 82: 722-724, 2006.
8. Chen HM, Chen CT, Yang H, Lee MI, Kuo MY, Kuo YS, Wang YP, Tsai T and Chiang CP: Successful treatment of an extensive verrucous carcinoma with topical 5-aminolevulinic acid-mediated photodynamic therapy. J Oral Pathol Med 34: 253-256, 2005.
9. Hopper C, Kubler A, Lewis H, Tan IB and Putnam G: mTHPC-mediated photodynamic therapy for early oral squamous cell carcinoma. Int J Cancer 10: 138-146, 2004.
10. Kubler AC, de Carpentier J, Hopper C, Leonard AG and Putnam G: Treatment of squamous cell carcinoma of the lip using Foscan-mediated photodynamic therapy. Int J Oral Maxillofac Surg 30: 504-509, 2001.
11. Palumbo G: Photodynamic therapy and cancer: a brief sightseeing tour. Expert Opin Drug Deliv 4: 131-148, 2007.
12. Nowis D, Makowski M, Stokłosa T, Legat M, Issat T and Golab J: Direct tumor damage mechanisms of photodynamic therapy. Acta Biochim Pol 52: 339-352, 2005,
13. Kusuzaki K, Minami G, Takeshita H, Murata H, Hashiguchi S, Nozaki T, Ashihara T and Hirasawa Y: Photodynamic inactivation with acridine orange on a multidrug-resistant mouse osteosarcoma cell line. Jpn J Cancer Res 91: 439-445, 2000.
14. Kusuzaki K, Aomori K, Suginoshita T, Minami G, Takeshita H, Murata H, Hashiguchi S, Ashihara T and Hirasawa Y: Total tumor cell elimination with minimum damage to normal tissues in musculoskeletal sarcomas by photodynamic reaction with acridine orange. Oncology 59: 174-180, 2000.
15. Kusuzaki K, Suginoshita T, Minami G, Aomori K, Takeshita H, Murata H, Hashiguchi S, Ashihara T and Hirasawa Y: Fluorovisualization effect of acridine orange on mouse osteosarcoma. Anticancer Res 20: 3019-3024, 2000.
16. Hashiguchi S, Kusuzaki K, Murata H, Takeshita H, Hashiba M, Nishimura T, Ashihara T and Hirasawa Y: Acridine orange excited by low-dose radiation has a strong cytocidal effect on mouse osteosarcoma. Oncology 62: 85-93, 2000.
17. Kusuzaki K, Murata H, Takeshita H, Hashiguchi S, Nozaki T, Emoto K, Ashihara T and Hirasawa Y: Intracellular binding sites of acridine orange in living osteosarcoma cells. Anticancer Res 20: 971-976,2000.
18. Kusuzaki K, Murata H, Matsubara T, Miyazaki S, Okamura A, Seto M, Matsumine A, Hosoi H, Sugimoto T and Uchida A: Clinical trial of photodynamic therapy using acridine orange with/without low dose radiation as new limb salvage modality in musculoskeletal sarcomas. Anticancer Res 25: 1225-1235, 2005.
19. Kusuzaki K, Murata H, Matsubara T, Miyazaki S, Shintani K, Seto M, Matsumine A, Hosoi H, Sugimoto T and Uchida A: Clinical outcome of a novel photodynamic therapy technique using acridine orange for synovial sarcomas. Photochem Photobiol 81: 705-709, 2005.
20. Yoshida K, Kusuzaki K, Matsubara, T, Matsumine A, Kumamoto T, Komada Y, Naka N and Uchida A: Periosteal Ewing's sarcoma treated by photodynamic therapy with acridine orange. Oncol Rep 13: 279-282, 2005.
21. Matsubara T, Kusuzaki K, Matsumine A, Shintani K, Satonaka H and Uchida A: Acridine orange used for photodynamic therapy accumulates in malignant musculoskeletal tumors depending on pH gradient. Anticancer Res 26: 187-193, 2006.
22. Satonaka H, Kusuzaki K, Matsubara T, Shintani K, Wakabayashi T, Matsumine A and Uchida A: Extracorporeal photodynamic image detection of mouse osteosarcoma in soft tissues utilizing fluorovisualization effect of acridine orange. Oncology 70: 465-473, 2006.
23. Kusuzaki K, Murata H, Matsubara T, Satonaka H, Wakabayashi T, Matsumine A and Uchida A: Acridine orange could be an innovative anticancer agent under photon energy. In Vivo 21: 205-214, 2007.
24. Satonaka H, Kusuzaki K, Matsubara T, Shintani K, Wakabayashi T, Nakamura T, Matsumine A and Uchida A: Flash wave light strongly enhanced the cytocidal effect of photodynamic therapy with acridine orange on a mouse osteosarcoma cell line. Anticancer Res 27: 3339-3344, 2007.
25. Bradberry SM: Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue. Toxicol Rev 22: 13-27, 2003.
26. Ajithkumar T, Parkinson C, Shamshad F and Murray P: Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol) 19: 108-114, 2007.
27. Cavaliere R and Schiff D: Neurologic toxicities of cancer therapies. Curr Neurol Neurosci Rep 6: 218-226, 2006.
28. Asai T, Ueda T, Itoh K, Yoshioka K, Aoki Y, Mori S and Yoshikawa H: Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer 76: 418-422, 1998.
29. Kalka K, Ahmad N, Criswell T, Boothman D and Mukhtar H: Up-regulation of clusterin during phthalocyanine 4 photodynamic therapy-mediated apoptosis of tumor cells and ablation of mouse skin tumors. Cancer Res 60: 5984-5987, 2000.
30. Ahmad N, Feyes DK, Agarwal R and Mukhtar H: Photodynamic therapy results in induction of WAF1/CIP1/P21 leading to cell cycle arrest and apoptosis. Cancer Res 60: 5984-5987, 2000.
31. Sherlock DJ and Holl-Allen RT: Intravital methylene blue staining of parathyroid glands and tumours. Ann R Coll Surg Engl 66: 396-398, 1984.
32. Meissner PE, Mandi G, Coulibaly B, Witte S, Tapsoba T, Mansmann U, Rengelshausen J, Schiek W, Jahn A, Walter-Sack I, Mikus G, Burhenne J, Riedel KD, Schirmer RH, Kouyate B and Muller O: Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Mala, J 8: 84, 2006.
33. Thite EM and Kelly JM: Photochemical interactions of methylene blue and analogues with DNA and other biological substrates. J Photochem Photobiol B 21: 103-124, 1993.
34. Gill WB, Taja A, Chadbourne DM, Roma M and Vermeulen CW: Inactivation of bladder tumor cells and enzymes by methylene blue plus light. J Urol 138: 1318-1320, 1987.
35. Yu DS, Chang SY and Ma CP: Photoinactivation of bladder tumor cells by methylene blue: study of a variety of tumor and normal cells. J Urol 144: 164-168, 1990.
36. Fowler GJ, Rees RC and Devonshire R: The photokilling of bladder carcinoma cells in vitro by phenothiazine dyes. Photochem Photobiol 52: 489-494, 1990.
37. Mellish KJ, Cox RD, Vernon DI, Griffiths J and Brown SB: In vitro photodynamic activity of a series of methylene blue analogues. Photochem Photobiol 75: 392-397, 2002.
38. Folkes LK and Wardman P: Enhancing the efficacy of photodynamic cancer therapy by radicals from plant auxin (indole-3-acetic acid). Cancer Res 15: 776-779, 2003.
39. Tang W, Xu H, Kopelman R and Philbert MA: Photodynamic characterization and in vitro application of methylene blue-containing nanoparticle platforms. Photochem Photobiol 81: 242-249, 2005.
40. Yu DS, Chang SY and Ma CP: Ultrastructural changes of bladder cancer cells following methylene blue-sensitized photodynamic treatment. Eur Urol 19: 322-326, 1991.
41. Williams JL, Stamp J, Devonshire R and Fowler GJ: Methylene blue and the photodynamic therapy of superficial bladder cancer. J Photochem Photobiol B 4: 229-232, 1989.